Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DRD2 | P14416 | 3/20 | 0.47 |
| ▸ | DRD3 | P35462 | 3/20 | 0.47 |
| ▸ | BCHE | P06276 | 3/20 | 0.38 |
| ▸ | ACHE | P22303 | 3/20 | 0.38 |
| ▸ | BACE1 | P56817 | 3/20 | 0.38 |
| ▸ | MEN1 | O00255 | 1/20 | 0.38 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.38 |
| ▸ | OPRM1 | P35372 | 1/20 | 0.38 |
| ▸ | OPRL1 | P41146 | 1/20 | 0.38 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.38 |
| ▸ | FUCA1 | P04066 | 2/20 | 0.37 |
| ▸ | CCR5 | P51681 | 1/20 | 0.36 |
| ▸ | DPP4 | P27487 | 1/20 | 0.36 |
| ▸ | PDE9A | O76083 | 1/20 | 0.36 |
| ▸ | GRIN2B | Q13224 | 2/20 | 0.36 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6318835 | 0.86 | DRD2 (0.43) | DRD2DRD3FUCA1GRIN2B | |
| SCHEMBL5747922 | 0.86 | DRD2 (0.46) | DRD2DRD3BCHEACHEBACE1 | |
| SCHEMBL6312037 | 0.77 | KDM1A (0.46) | DRD2DRD3ACHEFUCA1CCR5 | |
| SCHEMBL5746448 | 0.75 | DRD2 (0.44) | DRD2DRD3ACHEMEN1KMT2A | |
| SCHEMBL13196701 | 0.74 | DRD2 (0.41) | DRD2DRD3BCHEACHEBACE1 | |
| SCHEMBL13201180 | 0.74 | DRD2 (0.41) | DRD2DRD3BCHEACHEBACE1 | |
| SCHEMBL2803299 | 0.74 | DRD2 (0.41) | DRD2DRD3BCHEACHEBACE1 | |
| SCHEMBL1203774 | 0.73 | DPP4 (0.60) | DRD2DRD3BCHEACHEBACE1 | |
| SCHEMBL1203772 | 0.73 | DPP4 (0.60) | DRD2DRD3BCHEACHEBACE1 | |
| SCHEMBL25391591 | 0.73 | FUCA1 (0.45) | DRD2DRD3ACHEFUCA1GRIN2B |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20050043354-A1 | NK1 antagonist | PFIZER INC | 2005-02-24 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050043354-A1 | NK1 antagonist | TACR2, TACR1, TAC3 | DRD2 701/4885DRD3 948/4885BCHE 1258/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.